newsEuropean Commission grants first-of-a-kind biosimilar approval22 May 2024 | By Catherine Eckford (European Pharmaceutical Review)The approval means Sandoz’s Wyost® and Jubbonti® are the first biosimilars of denosumab authorised in Europe.
newsSandoz granted novel biosimilars approval6 March 2024 | By Catherine Eckford (European Pharmaceutical Review)The approval authorises the interchangeability of denosumab biosimilars in the US to treat primary and secondary bone loss.
newsFDA approves Prolia for glucocorticoid-induced osteoporosis24 May 2018 | By European Pharmaceutical ReviewThe FDA has approved the use of Prolia for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture...